RGC-32, or Response Gene to Complement 32, plays a pivotal role in mediating cellular responses following complement activation. Acting as a regulator of the cell cycle, RGC-32 is implicated in ...

Journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. Recent clinical trials utilizing high doses of adeno ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma. This is an ASCO Meeting ...

An MUSC research team reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that contribute to fetal brain inflammation and ...

Scientists have discovered novel immune responses that help explain how some individuals avoid getting COVID-19. Using single-cell sequencing, researchers studied immune responses against SARS-CoV-2 ...

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...